Sands BE, Irving PM, Hoops T, Izanec JL, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in
biologic-naive patients with moderately to severely active Crohn's disease: a
multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 2022;399:2200-2211.
PMID: 35691323